{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/prostatitis-acute/prescribing-information/levofloxacin/","result":{"pageContext":{"chapter":{"id":"7fc380fc-24a6-5224-9d35-019f77e2d24e","slug":"levofloxacin","fullItemName":"Levofloxacin","depth":2,"htmlHeader":"<!-- begin field 8c1a3dd8-0a49-42c0-b856-aa1700abdd1f --><h2>Levofloxacin</h2><!-- end field 8c1a3dd8-0a49-42c0-b856-aa1700abdd1f -->","summary":"","htmlStringContent":"<!-- begin item 93952d28-48d5-463d-90f4-aa1700abdcff --><!-- end item 93952d28-48d5-463d-90f4-aa1700abdcff -->","topic":{"id":"73f0b35c-c49b-5f10-bb40-54ecdda0c994","topicId":"e7655eee-79f9-435e-b34e-7e3dc9576eb5","topicName":"Prostatitis - acute","slug":"prostatitis-acute","lastRevised":"Last revised in November 2020","chapters":[{"id":"8803a04f-6c62-5033-ac75-2e0987df1dd9","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"23265380-0c8c-51f6-984e-87cbf6e27684","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"7f11e55f-ca93-5c30-86f8-fa21b370c650","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"aa21e1cb-1af6-5deb-b54b-9cb7a12a8a11","slug":"changes","fullItemName":"Changes"},{"id":"bc4d0c33-79f0-5fe0-8655-d9dbf99bbcf5","slug":"update","fullItemName":"Update"}]},{"id":"e29f027b-46a8-5ac6-b1b7-d063f673588e","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"e0a59bba-34f6-512a-b3f6-19ba509165b0","slug":"goals","fullItemName":"Goals"},{"id":"b99f36b6-4383-55b0-8d6f-72dfeed4d249","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"0629bcf7-67ce-5175-893c-bb0e770c16c1","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"6da14859-d882-5bd2-b686-021dc2ab43ca","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"90fb5a5f-3ae5-53d9-b871-bf93c899f97c","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"a78a1b88-9559-551a-880f-736efedb2497","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"c8ae728c-472f-509a-add8-39034e05aff0","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"816a1fba-211e-520e-87c1-c47a23e06dd3","slug":"definition","fullItemName":"Definition"},{"id":"42efdea9-f709-5243-8b5c-a2b75dbbba5f","slug":"causes","fullItemName":"Causes"},{"id":"9713a2ac-cc24-5443-9756-3e59fbcf65b8","slug":"prevalence","fullItemName":"Prevalence"},{"id":"d981ad36-33da-56db-bb45-f12d69fe5543","slug":"prognosis","fullItemName":"Prognosis"},{"id":"5b0439a7-9599-542f-b2b2-51d20cc566f2","slug":"complications","fullItemName":"Complications"}]},{"id":"6553966d-798f-5d17-bcd0-6f62f2f8b5bd","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"d539bec4-2427-585f-a83c-db984fc0d801","slug":"suspecting-acute-prostatitis","fullItemName":"Suspecting acute prostatitis"},{"id":"d1e691e6-d634-508e-a5c1-62018b5b24be","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"2e7dc7c5-dc32-59bf-9021-54b838ce5a9b","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"398acafd-0ba3-5cf1-8c9c-8d2ccca863ae","fullItemName":"Management","slug":"management","subChapters":[{"id":"8c56415b-f5bc-5fc1-b859-13b369ee963d","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"50977f3d-5737-50f5-9c23-c4a03b4539cf","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"c6f0cb41-8824-5f6b-9b63-19a56232237a","slug":"ciprofloxacin","fullItemName":"Ciprofloxacin"},{"id":"161382aa-bad2-5c17-9d1c-59f978dd6a83","slug":"ofloxacin","fullItemName":"Ofloxacin"},{"id":"6aee14ab-550d-5bdd-b0e4-d2febce26f7a","slug":"trimethoprim","fullItemName":"Trimethoprim"},{"id":"7fc380fc-24a6-5224-9d35-019f77e2d24e","slug":"levofloxacin","fullItemName":"Levofloxacin"},{"id":"fc84b330-890f-5ebf-b2cd-5724765b85a8","slug":"co-trimoxazole","fullItemName":"Co-trimoxazole"}]},{"id":"c4981733-d5d6-5190-b43d-7cdee7ac825c","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"137ffbc9-e5c4-5f58-bfc1-4d3afb883356","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"5f07d427-7c9b-521d-ba7a-1a7bc564f48d","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"05f5c8e4-6073-506c-909a-cef5c3cf622c","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"63ca9076-27d4-5254-9eda-bcbb43177d95","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"ff474396-1f31-58cd-b153-976c3894cafd","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"be6b66c2-c9cc-5d52-99dd-044e49dadfb0","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"9b5aeabb-1902-5659-8e0b-625f567b86e0","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"50977f3d-5737-50f5-9c23-c4a03b4539cf","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"b15fe56e-980d-5873-859d-dde32d6901fd","slug":"cautions-contraindications","fullItemName":"Cautions and contraindications","depth":3,"htmlHeader":"<!-- begin field 02616385-0e6a-49c6-aaba-aa1700ac03ba --><h3>Cautions and contraindications</h3><!-- end field 02616385-0e6a-49c6-aaba-aa1700ac03ba -->","summary":"","htmlStringContent":"<!-- begin item 88c12ee0-2cdb-442f-8cb1-aa1700ac0395 --><!-- begin field 54b2326e-9942-47e5-a61f-aa1700ac03ba --><ul><li><strong>Do not prescribe levofloxacin to people:</strong><ul><li>With epilepsy.</li><li>With a history of tendon disorders related to fluoroquinolone administration, or who have previously had serious adverse reactions with a quinolone or fluoroquinolone antibiotic.</li><li>Taking a corticosteroid — coadministration could exacerbate fluoroquinolone-induced tendonitis and tendon rupture.</li></ul></li><li><strong>Prescribe levofloxacin with caution to people with:</strong><ul><li>A history of tendonitis.</li><li>Aortic aneurysm and/or aortic dissection, a family history of aneurysm disease, or with risk factors or conditions predisposing for aortic aneurysm and dissection (for example, Marfan syndrome, vascular Ehlers-Danlos syndrome, Takayasu arteritis, giant cell arteritis, Behcet's disease, hypertension, known atherosclerosis).</li><li>A predisposition to seizures, or taking medicines that lower the seizure threshold (for example, theophylline). </li><li>Conditions which predispose to QT interval prolongation:<ul><li>Congenital long QT syndrome.</li><li>Concomitant use of drugs that are known to prolong the QT interval (for example Class IA and III anti-arrhythmics, tricyclic antidepressants, macrolides, antipsychotics).</li><li>Uncorrected electrolyte imbalance (for example hypokalaemia, or hypomagnesaemia).</li><li>Cardiac disease (for example, heart failure, myocardial infarction, or bradycardia).</li><li>Electrolyte disturbances.</li></ul></li><li>Diabetes mellitus — may affect blood glucose. Blood glucose should be monitored closely.</li><li>Glucose-6-phosphate dehydrogenase deficiency — haemolytic reactions have been reported.</li><li>History of a psychotic disorder — there have been reports of suicidal thoughts or self-endangering behaviour after use quinolones. </li><li>Myasthenia gravis — symptoms can be exacerbated.</li></ul></li><li>Also prescribe with caution in people aged over 60 years, people with renal impairment (dose adjustments may be required) or solid-organ transplants, as they are at a higher risk of tendon injury.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/prostatitis-acute/references/\">BNF 76, 2018</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/prostatitis-acute/references/\">ABPI, 2019c</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/prostatitis-acute/references/\">MHRA, 2019</a>]</p><!-- end field 54b2326e-9942-47e5-a61f-aa1700ac03ba --><!-- end item 88c12ee0-2cdb-442f-8cb1-aa1700ac0395 -->","subChapters":[]},{"id":"5f886bd3-35a9-5888-93ea-f52410b9747e","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field d734f8da-fa38-4ed0-98e4-aa1700ac16a9 --><h3>Adverse effects</h3><!-- end field d734f8da-fa38-4ed0-98e4-aa1700ac16a9 -->","summary":"","htmlStringContent":"<!-- begin item bcc42f3e-6a6a-4b74-ae5a-aa1700ac1688 --><!-- begin field 596a034d-d4b1-41b8-96e5-aa1700ac16a9 --><ul><li><strong>Cardiovascular</strong> — there is an increased risk of aortic aneurysm and dissection with fluoroquinolones, particularly in the older population. Fluoroquinolones should only be used after careful benefit-risk assessment and after consideration of other therapeutic options in people with positive family history of aneurysm disease, or in people diagnosed with pre-existing aortic aneurysm and/or aortic dissection, or in presence of other risk factors or conditions predisposing for aortic aneurysm and dissection (for example, Marfan syndrome, vascular Ehlers-Danlos syndrome, Takayasu arteritis, giant cell arteritis, Behcet’s disease, hypertension, known atherosclerosis).</li><li><strong>Gastrointestinal </strong>— diarrhoea, nausea, vomiting (common); abdominal pain, dyspepsia, flatulence (uncommon).<ul><li><strong>Very rarely:</strong> pseudomembranous colitis. For more information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/diarrhoea-antibiotic-associated/\">Diarrhoea - antibiotic associated</a>.</li></ul></li><li><strong>Hepatobiliary</strong> — hepatic enzyme increases (common); blood bilirubin increased (uncommon); jaundice, severe liver failure, hepatitis (frequency unknown).</li><li><strong>Musculoskeletal </strong>— arthralgia, myalgia (uncommon). <ul><li><strong>Rarely:</strong> tendon disorders (including tendonitis), muscular weakness — this may occur within 48 hours of starting treatment, or months after stopping. Risk of tendon rupture is increased by co-administration of corticosteroids and in people aged over 60 years. If tendonitis is suspected treatment should be stopped immediately. </li><li><strong>Frequency unknown: </strong>rhabdomyolysis, tendon rupture, ligament rupture. </li></ul></li><li><strong>Nervous system</strong> — headache, dizziness (uncommon); somnolence, tremor, dysgeusia (uncommon); convulsions (the CSM has warned that quinolones may induce convulsions in people with or without a history of convulsions; taking NSAIDs at the same time may also induce them).<ul><li><strong>Rarely:</strong> peripheral neuropathy, dyskinesia, syncope. </li></ul></li><li><strong>Psychiatric</strong> — insomnia (common); anxiety, confusional state, nervousness (uncommon)<ul><li><strong>Rarely:</strong> psychotic disorder with self-endangering behaviour including suicidal ideation or suicide attempt.</li></ul></li><li><strong>Skin</strong> — rash, pruritus, urticaria, hyperhidrosis (uncommon).<ul><li><strong>Rarely: </strong>Stevens-Johnson syndrome, erythema multiforme, toxic epidermal necrolysis anaphylaxis.</li></ul></li><li><strong>Other adverse effects include: </strong><ul><li>Anaphylaxis.</li><li>Dyspnoea, bronchospasm.</li><li>Renal impairment.</li><li>Tachycardia, palpitations.</li><li>Vertigo, tinnitus.</li><li>Visual disturbances.</li></ul></li><li><strong>NOTE: </strong>fluoroquinolones can very rarely cause long-lasting (up to months or years), disabling, and potentially irreversible side effects, sometimes affecting multiple systems, organ classes, and senses. People should be advised to stop treatment at the first signs of a serious adverse reaction, such as tendonitis or tendon rupture, muscle pain, muscle weakness, joint pain, joint swelling, peripheral neuropathy, and central nervous system effects, and to contact their doctor immediately for further advice.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/prostatitis-acute/references/\">BNF 76, 2018</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/prostatitis-acute/references/\">ABPI, 2019c</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/prostatitis-acute/references/\">MHRA, 2019</a>]</p><!-- end field 596a034d-d4b1-41b8-96e5-aa1700ac16a9 --><!-- end item bcc42f3e-6a6a-4b74-ae5a-aa1700ac1688 -->","subChapters":[]},{"id":"f13f9dfd-38f4-53d8-a09a-99238d35bab3","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field a7c29134-821b-43b3-898d-aa1700ac2526 --><h3>Drug interactions</h3><!-- end field a7c29134-821b-43b3-898d-aa1700ac2526 -->","summary":"","htmlStringContent":"<!-- begin item 0f5639a7-c0a3-4865-806d-aa1700ac24eb --><!-- begin field fcfad470-f1e4-437a-af94-aa1700ac2526 --><ul><li><strong>Antacids (containing aluminium, calcium, or magnesium) and other medications containing iron or zinc </strong>— these may reduce the absorption of levofloxacin if taken concurrently.<ul><li>Levofloxacin should be taken at least 2 hours before these preparations and not less than 4 to 6 hours after them. </li></ul></li><li><strong>Corticosteroids</strong> — the risk of tendonitis and tendon rupture is increased in people taking a fluoroquinolone and a corticosteroid. The MHRA advises that concurrent should be avoided. </li><li><strong>Domperidone</strong> — the manufacturer advises that concurrent use with levofloxacin should be avoided as it may lead to QT interval prolongation.</li><li><strong>Mizolastine</strong> — the manufacturer advises that concurrent use should be avoided. Mizolastine has a weak potential to cause QT interval prolongation in some people and this may be additive to the effects of levofloxacin.</li><li><strong>Nonsteroidal anti-inflammatory drugs (NSAIDs) </strong>— possible increased risk of seizures when quinolones are given with NSAIDs. Avoid concurrent use in people with epilepsy or people predisposed to seizures, or monitor them very closely.</li><li><strong>Oral hormonal contraception</strong> — additional contraceptive precautions are not required during or after courses of levofloxacin.<ul><li>However, women should be advised about the importance of correct contraceptive practice if they experience vomiting or diarrhoea. For further information, see the sections on vomiting or diarrhoea in the CKS topics on <a class=\"topic-reference external-reference\" href=\"/topics/contraception-combined-hormonal-methods/\">Contraception - combined hormonal methods</a> and <a class=\"topic-reference external-reference\" href=\"/topics/contraception-progestogen-only-methods/\">Contraception - progestogen-only methods</a>.</li></ul></li><li><strong>Strontium ranelate </strong>— the absorption of quinolones is reduced by strontium ranelate so they should not be given together.</li><li><strong>Tacrolimus</strong> — levels are increased slightly when taken concurrently with levofloxacin. Consider increased monitoring if levofloxacin is started or stopped.</li><li><strong>Theophylline </strong>— levofloxacin does not affect plasma levels of theophylline, however there has been a report of theophylline toxicity and reports of seizures in people given theophylline and a quinolone. Theophylline can cause hypokalaemia increasing the risk of torsade de pointes which may be additive with that the effects of levofloxacin. Monitor potassium concentration closely.</li><li><strong>Warfarin </strong>— rarely, levofloxacin may enhance the anticoagulant effect, increasing the risk of bleeding. Monitor the international normalised ratio (INR) within 3 to 5 days of starting levofloxacin, frequently during and shortly after administration.</li><li><strong>Zolmitriptan </strong>— quinolones increase the plasma concentration of zolmitriptan by inhibiting its metabolism. Manufacturer recommends a maximum dose of 5 mg in 24 hours in people taking a quinolone.</li><li><strong>Drugs that prolong the QT interval </strong>(such as Class IA and III anti-arrhythmics, tricyclic antidepressants, macrolides, and antipsychotics) — very rare cases of QT interval prolongation have been reported in people taking quinolones and they should therefore be prescribed with caution alongside drugs known to prolong the QT interval.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/prostatitis-acute/references/\">Preston, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/prostatitis-acute/references/\">BNF 76, 2018</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/prostatitis-acute/references/\">ABPI, 2019c</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/prostatitis-acute/references/\">MHRA, 2019</a>]</p><!-- end field fcfad470-f1e4-437a-af94-aa1700ac2526 --><!-- end item 0f5639a7-c0a3-4865-806d-aa1700ac24eb -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}